Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans.

Nahler G, Grotenhermen F, Zuardi AW, Crippa JAS.

Cannabis Cannabinoid Res. 2017 May 1;2(1):81-86. doi: 10.1089/can.2017.0009. eCollection 2017.

2.
3.

Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.

Merrick J, Lane B, Sebree T, Yaksh T, O'Neill C, Banks SL.

Cannabis Cannabinoid Res. 2016 Apr 1;1(1):102-112. doi: 10.1089/can.2015.0004. eCollection 2016.

4.

Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN.

Järbe TU, Henriksson BG, Ohlin GC.

Arch Int Pharmacodyn Ther. 1977 Jul;228(1):68-72.

PMID:
921403
5.

Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.

Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T.

Eur Neuropsychopharmacol. 2017 Dec;27(12):1223-1237. doi: 10.1016/j.euroneuro.2017.10.037. Epub 2017 Nov 10.

PMID:
29129557
6.

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.

Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T.

Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76. doi: 10.1017/S1461145709990605. Epub 2009 Sep 29.

PMID:
19785914
8.

Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036.

Bonn-Miller MO, Banks SL, Sebree T.

Cannabis Cannabinoid Res. 2017 Jan 1;2(1):5-7. doi: 10.1089/can.2016.0038. eCollection 2017.

10.

Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM.

Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77. doi: 10.1016/j.euroneuro.2008.04.008. Epub 2008 Jun 10.

PMID:
18544469
11.

Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD.

Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, Vandelli MA, Forni F, Cannazza G.

J Pharm Biomed Anal. 2018 Feb 20;150:25-32. doi: 10.1016/j.jpba.2017.11.054. Epub 2017 Nov 28.

PMID:
29202305
12.

Antineoplastic activity of cannabinoids.

Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA.

J Natl Cancer Inst. 1975 Sep;55(3):597-602.

PMID:
1159836
13.

Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, Deutsch DG.

J Biol Chem. 2015 Apr 3;290(14):8711-21. doi: 10.1074/jbc.M114.618447. Epub 2015 Feb 9.

14.

Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102-112; DOI: 10.1089/can.2015.0004.

Grotenhermen F, Russo E, Zuardi AW.

Cannabis Cannabinoid Res. 2017 Jan 1;2(1):1-4. doi: 10.1089/can.2016.0036. eCollection 2017.

15.

Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.

Jacobs DS, Kohut SJ, Jiang S, Nikas SP, Makriyannis A, Bergman J.

Exp Clin Psychopharmacol. 2016 Oct;24(5):320-330. Epub 2016 Aug 15.

16.

Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.

Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z.

J Biol Chem. 2010 Jan 15;285(3):1616-26. doi: 10.1074/jbc.M109.069294. Epub 2009 Nov 12.

17.

Influence of cannabidiol on delta-9-tetrahydrocannabinol effects.

Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB.

Clin Pharmacol Ther. 1976 Mar;19(3):300-9.

PMID:
770048
18.

Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.

Ross HR, Napier I, Connor M.

J Biol Chem. 2008 Jun 6;283(23):16124-34. doi: 10.1074/jbc.M707104200. Epub 2008 Apr 7.

19.

Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.

Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F.

J Anal Toxicol. 2005 Nov-Dec;29(8):782-9.

PMID:
16356335
20.

Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells.

Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Coppola G, Geschwind D, Vogel Z.

Br J Pharmacol. 2012 Apr;165(8):2512-28. doi: 10.1111/j.1476-5381.2011.01461.x.

Supplemental Content

Support Center